Skip to main content
Figure 2 | BMC Health Services Research

Figure 2

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Figure 2

Kaplan-Meier survival analysis for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2 targeted agents and matched comparison patients. Note: Median survival for the study cohort was 23 months and it was not reached for the comparison cohort during the study period.

Back to article page
\